Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.17M Sell
8,628
-136
-2% -$29.3K 0.6% 36
2026
Q1
$1.91M Buy
8,764
+1,149
+15% +$255K 0.66% 34
2025
Q4
$1.74M Sell
7,615
-293
-4% -$66.7K 0.61% 41
2025
Q3
$1.66M Buy
7,908
+4,423
+127% +$901K 0.65% 39
2025
Q2
$730K Hold
3,485
0.34% 70
2025
Q1
$730K Buy
3,485
+230
+7% +$44.7K 0.34% 70
2024
Q4
$578K Buy
3,255
+3
+0.1% +$552 0.25% 87
2024
Q3
$642K Sell
3,252
-199
-6% -$37.1K 0.29% 84
2024
Q2
$592K Sell
3,451
-102
-3% -$16.9K 0.28% 83
2024
Q1
$647K Buy
3,553
+26
+0.7% +$4.48K 0.31% 85
2023
Q4
$547K Buy
+3,527
New +$514K 0.27% 94
2023
Q3
Sell
-2,236
Closed -$301K 57
2023
Q2
$301K Sell
2,236
-17
-0.8% -$2.49K 0.16% 130
2023
Q1
$359K Buy
2,253
+59
+3% +$9.02K 0.2% 122
2022
Q4
$355K Sell
2,194
-1
-0% -$153 0.2% 113
2022
Q3
$315K Buy
2,195
+200
+10% +$28.7K 0.19% 107
2022
Q2
$306K Sell
1,995
-53
-3% -$8.1K 0.19% 113
2022
Q1
$332K Sell
2,048
-32
-2% -$4.65K 0.18% 104
2021
Q4
$285K Buy
+2,080
New +$246K 0.16% 97

Other funds holding ABBV

Saxon Interests's ABBV Position: Q2 2026 in Review

Saxon Interests reduced its AbbVie (ABBV) stake by 1.6% in Q2 2026, selling an estimated $29.3K and leaving 8,628 shares worth $2.17M. The position accounts for 0.6% of the portfolio, ranked #36.

Saxon Interests first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. 4,206 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Saxon Interests held 8,628 shares of AbbVie worth $2.17M as of Q2 2026.
  • Saxon Interests sold 136 AbbVie shares in Q2 2026, an estimated $29.3K.
  • AbbVie made up 0.6% of Saxon Interests's portfolio in Q2 2026, its #36 holding.
  • Saxon Interests first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
  • 4,206 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Saxon Interests's 13F filing for Q2 2026, filed 12 Aug 2026.